GSK PLC GSK StarRatingValueLabel_4Damien Conover, CFA - Sector Director - Morningstar Inc.

Last Price
1,599.00
Day Change
15.50|0.98%

As of 19/04/2024
18:12:29 BST | GBX  Minimum 15 Minutes Delay.

Bid/OfferDay RangeVolume90d Ave VolMkt Cap
1,538.00 - 1,650.001,575.00 - 1,600.005,148,9769,043,19865.34Bil
Last Close52 Week RangeP/EYield %ISIN
1,583.501,302.60 - 1,719.8013.343.63GB00BN7SWP63

GSK Share Price

Morningstar's Take GSK

As one of the largest pharmaceutical and vaccine companies, GSK has used its vast resources to create the next generation of healthcare treatments. The company's innovative new product lineup and expansive list of patent-protected drugs create a wide economic moat, in our opinion.

Fair Value Estimate

2,200.00 GBX

Uncertainty

Average

Economic Moat

Wide

Financial Strength

Financial Strength
There is no one analyst in which a Quantitative Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible for overseeing the methodology that supports the quantitative fair value. As an employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.’s Code of Ethics and Personal Securities Trading Policy in carrying out his responsibilities. For information regarding Conflicts of Interests, click here.

Total Returns 19/04/2024

 Chg (%)  
GSK PLC-3.93 
FTSE 100 TR GBP2.43
 
Financials
202120222023
more...
Income Statement
Turnover24,696.0029,324.0030,328.00
Operating Profit4,878.006,729.007,345.00
Net Profit3,516.004,921.005,308.00
Reported EPS81.80109.20119.90
Balance Sheet
Current Assets18,652.0020,671.0018,568.00
Non Current Assets60,429.0039,377.0040,361.00
Total Assets79,103.0060,146.0059,005.00
Current Liabilities23,670.0022,810.0021,068.00
Total Liabilities57,761.0050,050.0046,210.00
Total Equity21,342.0010,096.0012,795.00
Cash Flow
Operating Cash Flow8,924.008,713.008,096.00
Net Change in Cash-1,414.00-546.00-468.00

Regulatory News

DateAuthor Headline
28/03/2024James Gard Top FTSE 100 UK Dividend Paying Stocks - ISA Season Special
UPDATED for March 2024: Changing tax rules and shifting markets mean UK investors with stocks and shares ISAs can be glad of some much-needed momentum
19/02/2024Jocelyn Jovene Europe's Magnificent 7 Stocks Are Profitable - And Cheaper
Four years ago analysts at Goldman Sachs came up with the GRANOLAS acronym for Europe's leading stocks
05/02/2024Fernando Luque Growth & Tech Stocks Lead Gains at Start of Year
Our first markets barometer of the new year shows growth equities remain in favour after outperforming value through 2023
Director Dealings
TradedActionNotifierPriceAmountValue
more...
16/04/2024PurchaseDr. Hal V Barron19.905,812115,642.00
16/04/2024DDr. Hal V Barron20.4085417,422.00
16/04/2024DMs. Emma N. Walmsley1,629.001,27920,835.00
16/04/2024DMs. Emma N. Walmsley1,611.281,84129,664.00

Company Profile

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Sector

Healthcare

Industry

Drug Manufacturers - General

Stock Style

Large-Blend

Fiscal Year Ends

December

Employees

70,200

Next Event 01/05/2024

First Quarter Results
Ratios
Comp
PER (E)13.88
Div Yld (E)3.48
PEG (E)0.00
ROCE17.90
Op Mrgn24.20
EPS Grwth0.14
Dividends
PreviousLatest
more...
Record Date17/11/2323/02/24
Ex-Div16/11/2322/02/24
Paid11/01/2411/04/24
Amnt14.0016.00
Directors
more...
Non-Executive DirectorDr. Hal V Barron
Non-Executive Director, ChairmanSir Jonathan Richard Symonds CBE
Non-Executive DirectorMr. Urs Rohner
Non-Executive Director, Senior Independent DirectorMr. Charles A. Bancroft
Company SecretaryMrs. Victoria Anne Whyte
Non-Executive DirectorMs. Wendy Becker
Non-Executive DirectorDr. Vishal Sikka
Executive Director, Chief Executive OfficerMs. Emma N. Walmsley
Executive Director, Chief Financial OfficerMs. Julie Brown
Non-Executive DirectorDr. Jesse Goodman, M.D.,M.P.H.
Non-Executive DirectorMs. Elizabeth McKee Anderson
Non-Executive DirectorDr. Anne Beal
Non-Executive DirectorDr. Harry C Dietz
Damien Conover, CFA - Sector Director - Morningstar Inc.
The conduct of Morningstar's analysts is governed by Morningstar's Code of Ethics, Securities Trading and Disclosure Policy, and Investment Research Integrity Policy. For information regarding conflicts of interest, please click here.
Fair Value is derived from a detailed projection of a company’s future cash flows. Analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. Combining analysts’ financial forecasts with the firm’s economic moat helps us assess how long returns on invested capital are likely to exceed the firm’s cost of capital. Because we are modeling free cash flow to the firm—representing cash available to provide a return to all capital providers—we discount future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights. If our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Qualitative Fair Value, please click here.
© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures